Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST

Trial Profile

Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Regorafenib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms GEIS; ISG; REGISTRI
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
    • 26 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top